Importance of serum p53 antibodies during follow-up after treatment of invasive bladder tumors

Urologia Internationalis

Volumn 72, Issue 4, 2004, Pages 292-298

  Gumus, Eyup ^a,c   Demirel, Gulderen ^b   Tanriverdi, Orhan ^a   Horasanli, Kaya ^a   Özmen, Gökhan ^a   Miroglu, Cengiz ^a  

^a SISLI ETFAL TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b Dr Pakize i Tarzi Laboratuarlari Turkey   (Turkey)

^c Barbaros Mah Sirma Perde Sok   (Turkey)

Author keywords

Anti p53 antibody; Bladder cancer, treatment, follow up; ELISA; p53

Indexed keywords

PROTEIN ANTIBODY; PROTEIN P53;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; BLADDER CARCINOMA; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; COMORBIDITY; CONTROL GROUP; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; FEMALE; FOLLOW UP; HUMAN; INVASIVE CARCINOMA; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; SEROLOGY; TRANSITIONAL CELL CARCINOMA;

ADULT; AGED; ANTIBODIES; CARCINOMA, TRANSITIONAL CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 2942557460     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000077680     Document Type: Article

References (27)

1. Tiguert R, Lessard A, So A, Fradet Y: Prognostic markers in muscle invasive bladder cancer. World J Urol 2002;20:190-195.
2. Stein JP, Grossfeld GD, Ginsberg DA, Esrig D, Freeman JA, Figueroa AJ, Skinner DG, Cote RJ: Prognostic markers in bladder cancer: A contemporary review of the literature. J Urol 1998;160:645-659.
3. Crawford LW, Pim DC, Bulbrook RD: Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 1982;30:403-408.
4. Davidoff AM, Iglehart JD, Marks JR: Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc Natl Acad Sci USA 1992;89:3439-3442.
5. Saffroy R, Lelong JC, Azoulay D, Salvucci M, Rcynes M, Bismuth H, Debuire B, Lemoine A: Clinical significance of circulating anti-p53 antibodies in European patients with hepatocelluler carcinoma. Br J Cancer 1999;79:604-610.
6. Mack U, Ukene D, Montenarh M, Sybrecht GW: Serum anti-p53 antibodies in patients with lung cancer. Oncol Rep 2000;7:669-674.
7. Shiota G, Ishida M, Noguchi N, Oyama K, Takano Y, Okuba M: Circulating p53 antibody in patients with colorectal cancer: Relation to clinicopathologic features and survival. Dig Dis Sci 2000;45:122-128.
8. Wild CP, Ridanpaa M, Anttila S, Lubin R, Soussi T, Husgafvel-Fursiainen K, Vainino H: p53 antibodies in the sera of lung cancer patients: Comparison with p53 mutation in the tumor tissue. Int J Cancer 1995;64:176-181.
9. Morita T, Tachikawa N, Kumomaru T, Nukui A, Ikeda H, Suzuki K, Tokue A: Serum antip53 antibodies and p53 protein status in the sera and tumours from bladder cancer patients. Eur Urol 2000;37:79-84.
10. Lang C, Unteregger S, Kartarius S, Günther J, Bonkhoff H, Montenarh M, Zwergel T: p53 autoantibodies in patients with urological tumours. Br J Urol 1998;82:721-726.
11. Wunderlich H, Hindermann W, Hüller M, Reichelt O, Werner W, Schubert J, Kosmehl H: The correlation of p53 protein overexpression and p53 antibodies in serum of patients with transitional cell carcinoma of the urinary bladder. Urol Int 2000;64:13-17.
12. Carbayo M, Chulia MT, Niveiro M, Aranda I, Mira A, Soria F: Autoantibodies against p53 protein in patients with transitional cell carcinoma of the bladder. Anticancer Res 1999;19:3531-3537.
13. Soussi T: p53 antibodies in the sera of patients with various types of cancer: A review. Cancer Res 2000;60:1777-1788.
14. Zalcman G, Schlichtholz B, Tredaniel J, Urban T, Lubin R, Dubois I, Milleron B, Hirsch A, Soussi T: Monitoring of p53 autoantibodies in lung cancer during therapy: Relationship to response to treatment. Clin Cancer Res 1998;4:1359-1366.
15. Regele S, Vogl FD, Kohler T, Kreinberg R, Runnebaum IB: p53 autoantibodies can be indicative of the development of breast cancer relapse. Anticancer Res 2003;23:761-764.
16. Shimada H, Kitabayashi H, Nabeya Y, Okazumi S, Matsubara H, Funami Y: Treatment response and prognosis of patients after recurrence of esophageal cancer. Surgery 2003;133:24-31.
17. TNM Classification of Malignant Tumours, ed 3. Geneva, International Union against Cancer, 1978.
18. Mostofi FK, Sobin LH, Torloni H: Histological Typing of Urinary Bladder Tumours. Geneva, World Health Organization, 1973.
19. Sternberg CN, Yagoda A, Scher HI, Watson RC, Ahmed T, Weiselberg LR, Geller N, Hollander PS, Herr HW, Sogani PC, Morse MJ, Whitmore WF: Preliminary result of M-VAC (methotrexate, vinblastine, doxorobucin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 1985;133:403-407.
20. Hammel P, Boissier B, Chauniette MT, Piedbois P, Rotman N, Kouyoumdjian JC, Lubin R, Delchier JC, Soussi T: Detection and monitoring of serum p53 antibodies in patients with colorectal cancer. Gut 1997;40:356-361.
21. Gadduci A, Ferdeghini M, Buttitta F, Cosio S, Fannuchi A, Annicchiarico C, Genazzani AR: Serum anti-p53 antibodies in the follow-up of patients with advanced ovarian carcinoma. Anticancer Res 1998;18:3763-3766.
22. Slaton JW, Benedict WF, Dinney CPN: p53 in bladder cancer: Mechanism of action, prognostic value, and target for therapy. Urology 2001;57:852-859.
23. Esrig D, Elmajian D, Groshen S, Freeman JA, Stein JP, Chen SC, Nichols PW, Skinner DG, Jones PA, Cote RJ: Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994;331:1259-1264.
24. Sarkis AS, Bajorin DF, Reuter VE, Herr HW, Netto G, Zhang ZF, Schultz PK, Cordon-Cardo C, Scher HI: Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J Clin Oncol 1995;13:1384-1390.
25. Herr HW, Bajorin DF, Scher HI: Neoadjuvant chemotherapy and bladder sparing surgery for invasive bladder cancer: Ten-year outcome. J Clin Oncol 1998;1:127-133.
26. Freiha FS, Reese J, Torti FM: A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle-invasive bladder cancer. J Urol 1996;152:495-500.
27. Skinner DG, Daniels JR, Russel CA: The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: A prospective comparative trial. J Urol 1991;145:459-467.